Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lorcaserin Advisory Committee Will Again Be Weighed Down By Safety Concerns

May 08 2012

• By Cathy Dombrowski

Related Content

Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study

Feb 22 2012

Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden

Feb 27 2012

With SPA Finalized, Orexigen To Begin CV Outcomes Study For <em>Contrave</em> In Second Quarter

Feb 06 2012

CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement

Mar 30 2012

Lorcaserin Re-Review Expected To Address Risk/Benefit Trade-offs, Rat Tumors

Mar 16 2012

Arena Must Deal With Rat Neoplasms To Move Forward With <i>Lorqess</i>

Sep 20 2010

FDA Issues Complete Response Letter for Arena's Lorcaserin

Oct 24 2010

Related Companies

Arena Pharmaceuticals, Inc.

Orexigen Therapeutics, Inc.

Vivus, Inc.

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window